Evidence map›Paper›PMID 41001036›Full record

ReviewFrontiers in oncology2025

Significance of ARID1A in neuroblastoma onset mechanism.

Duo Jin, Dong Zhang, Qinyu Tang

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Duo Jin *Comprehensive Laboratory, The First People's Hospital of Changzhou, Changzhou, China.
Dong Zhang *The Ruminant Disease Early Warning, Prevention and Control Technology Innovation Team, Institute of Special Wild Economic Animals and Plants, Chinese Academy of Agricultural Sciences, Changchun, China.
Qinyu Tang *Department of Dermatology, The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma (NB) is a prevalent pediatric malignancy with poor clinical outcomes. As one of the most common childhood malignancies, it can arise in various locations along the sympathetic nervous system, complicating both fundamental studies and therapeutic approaches. The ARID1A protein has emerged as a pivotal regulator in the pathogenesis of diverse tumor types within oncology research. Recent studies have increasingly focused on the functional role of ARID1A in NB pathogenesis. As a tumor suppressor, ARID1A loss-of-function mutations enhance migratory and invasive capacities of NB cells through cell cycle dysregulation, thereby promoting tumor cell proliferation. At the molecular level, ARID1A functions as the core subunit of the BAF chromatin remodeling complex, critically regulating the proliferative behavior of tumor cells. Although research in this field remains at an early stage, it has established a solid foundation for elucidating NB pathogenesis, with promising implications for improving clinical outcomes and quality of life in affected children. This review summarizes the critical role of ARID1A in NB and explores emerging therapeutic strategies, with particular emphasis on targeted protein degradation approaches and immunotherapeutic interventions.

Indexed as

ARID1ABAF complexMYCNneuroblastomatreatment

Identifiers

PMID41001036
PMCPMC12457130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.